Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.88 |
| ▸ | CA1 | P00915 | 4/20 | 0.88 |
| ▸ | CA2 | P00918 | 4/20 | 0.88 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.88 |
| ▸ | PARP1 | P09874 | 1/20 | 0.88 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.88 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.75 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.65 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.65 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.63 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.59 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.59 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.59 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.59 |
| ▸ | CES2 | O00748 | 1/20 | 0.59 |
| ▸ | CES1 | P23141 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL201761 | 0.94 | PARP10 (1.00) | PARP10CA1CA2PARP4PARP1 | |
| Hydrochloric Acid SCHEMBL408766 | 0.91 | PARP10 (0.95) | PARP10CA1CA2PARP4PARP1 | |
| Hydrochloric Acid SCHEMBL4376056 | 0.91 | PARP10 (0.95) | PARP10CA1CA2PARP4PARP1 | |
| SCHEMBL27571315 | 0.88 | PARP10 (0.88) | PARP10CA1CA2PARP4PARP1 | |
| Acetic Acid SCHEMBL28396208 | 0.88 | PARP10 (0.88) | PARP10CA1CA2PARP4PARP1 | |
| SCHEMBL5836337 | 0.88 | PARP10 (1.00) | PARP10CA1CA2PARP4PARP1 | |
| SCHEMBL28188209 | 0.86 | RXRA (0.71) | PARP10CA1CA2PARP4PARP1 | |
| SCHEMBL8406724 | 0.86 | PARP10 (0.84) | PARP10CA1CA2PARP4PARP1 | |
| Ethylene Glycol SCHEMBL1232077 | 0.86 | PARP10 (0.84) | PARP10CA1CA2PARP4PARP1 | |
| SCHEMBL11600003 | 0.86 | PARP10 (0.84) | PARP10CA1CA2PARP4PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101437800-A | Compounds and compositions as HEDGEHOG pathway modulators | IRM LLC (BM) | 2009-05-20 | — | — | CN | claimed |
| CN-115872947-B | Benzisothiazole benzamide compound or pharmaceutically acceptable salt thereof, preparation method and application | 中国药科大学 | 2024-04-19 | — | — | CN | disclosed |
| WO-2017064490-A1 | CROSS-LINKABLE CHARGE TRANSPORT MATERIALS | LOMOX LIMITED (GB) | 2017-04-20 | — | — | WO | disclosed |
| CN-101437800-A | Compounds and compositions as HEDGEHOG pathway modulators | IRM LLC (BM) | 2009-05-20 | — | — | CN | disclosed |
| CN-1115330-C | N- (4-amidinophenyl) glycinamide derivatives | HOFFMANN LA ROCHE (CH) | 2003-07-23 | — | — | CN | disclosed |
| US-6410547-B1 | (4-OXY-3-(ARYL)PHENYL)PYRIDINE FOR TREATMENT, PROPHYLAXIS OF INFLAMMATION, ESP. INFLAMMATORY OR OBSTRUCTIVE DISEASES OF THE AIRWAYS, E.G. FOR ASTHMA THERAPY; INHIBITORS OF PDE 4 ISOENZYME; DOWN REGULATE OR INHIBIT TNF-ALPHA RELEASE | NOVARTIS AG (CH) | 2002-06-25 | — | — | US | disclosed |
| US-20020028831-A1 | Phenylpyridine derivatives useful as phosphodiesterase inhibitors | MANLEY PAUL W (CH) | 2002-03-07 | — | — | US | disclosed |
| US-6288092-B1 | BIPHENYL PYRIDINES, BENZAMIDES AND PENYLCARBOXY COMPOUNDS USED AS SELECTIVE INHIBITORS OF PHOSPHODIESTERASE 4 ISOENZYME ACTIVITY AND DOWN REGULATORS OR INHIBIT TUMOR NECROSIS FACTOR RELEASE; ANTIHISTAMINES AND ANTIINFLAMMATORY | NOVARTIS AG (CH) | 2001-09-11 | — | — | US | disclosed |
| US-6258843-B1 | DRUGS AS ENZYME INHIBITORS | NOVARTIS AG (CH) | 2001-07-10 | — | — | US | disclosed |
| US-6160157-A | Preparation of 4-cyano-4'-hydroxybiphenyl | SOCIETE D'EXPANSION SCIENTIFIQUE EXPANSIA (FR) | 2000-12-12 | — | — | US | disclosed |
| US-6090817-A | Phenylpyridine derivatives useful as phosphodiesterase inhibitors | NOVARTIS AG (CH) | 2000-07-18 | — | — | US | disclosed |
| EP-0970045-A1 | PREPARATION OF 4-CYANO-4'-HYDROXY BIPHENYL | Société d'Expansion Scientifique Expansia (FR) | 2000-01-12 | — | — | EP | disclosed |
| CN-1224714-A | N- (4-amidinophenyl) glycinamide derivatives | HOFFMANN LA ROCHE (CH) | 1999-08-04 | — | — | CN | disclosed |
| EP-0885193-A1 | TRIARYL COMPOUNDS | Novartis AG (CH) | 1998-12-23 | — | — | EP | disclosed |
| WO-1998037060-A1 | PREPARATION OF 4-CYANO-4'-HYDROXY BIPHENYL | SOCIETE D'EXPANSION SCIENTIFIQUE EXPANSIA (FR) | 1998-08-27 | — | — | WO | disclosed |
| WO-1997032853-A1 | TRIARYL COMPOUNDS | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | disclosed |
| CN-1090282-A | The cycloalkyl that benzenefused, hydroxy replaces and the sulfone amide derivative of heterogeneous ring compound | PFIZER (US) | 1994-08-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028831-A1 | Phenylpyridine derivatives useful as phosphodiesterase inhibitors | PDE4A, PDE4B, PDE12 | PARP10 2254/4885CA1 3809/4885CA2 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.